The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Open Access
- 1 September 2015
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 156 (9) , 3114-3121
Abstract
Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, inappropriately low serum PTH concentrations and hypercalciuria. Negative allosteric CaSR modulators, known as calcilytics, have been shown to normalize the gain-of-function associated with ADH-causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However, the effectiveness of calcilytic drugs for the treatment of ADH1-associated hypocalcemia remains to be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1 by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain-of-function CaSR mutation, Leu723Gln. Wild-type (Leu723) and Nuf mutant (Gln723) CaSRs were expressed in HEK293 cells, and the effect of NPS 2143 on their intracellular calcium responses was determined by flow cytometry. NPS 2143 was also administered as a single ip bolus to wild-type and Nuf mice and plasma concentrations of calcium and PTH, and urinary calcium excretion measured. In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells expressing the mutant Gln723 CaSR in a dose-dependent manner, thereby rectifying the gain-of-function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in Nuf mice led to significant increases in plasma calcium and PTH without elevating urinary calcium excretion. These studies of a mouse model with an activating CaSR mutation demonstrate NPS 2143 to normalize the gain-of-function causing ADH1 and improve the hypocalcemia associated with this disorder.Keywords
This publication has 34 references indexed in Scilit:
- An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formationBone, 2010
- Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemiaEndocrine-Related Cancer, 2009
- Rescue of Calcium-sensing Receptor Mutants by Allosteric Modulators Reveals a Conformational Checkpoint in Receptor BiogenesisJournal of Biological Chemistry, 2007
- A Missense Mutation in the Seven-transmembrane Domain of the Human Ca2+ Receptor Converts a Negative Allosteric Modulator into a Positive Allosteric ModulatorJournal of Biological Chemistry, 2006
- A Region in the Seven-transmembrane Domain of the Human Ca2+ Receptor Critical for Response to Ca2+Journal of Biological Chemistry, 2005
- Homology Modeling of the Transmembrane Domain of the Human Calcium Sensing Receptor and Localization of an Allosteric Binding SiteJournal of Biological Chemistry, 2004
- Calcilytic Compounds: Potent and Selective Ca2+Receptor Antagonists That Stimulate Secretion of Parathyroid HormoneThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Comparison of Hypocalcemic Hypercalciuria between Patients with Idiopathic Hypoparathyroidism and Those with Gain-of-Function Mutations in the Calcium-Sensing Receptor: Is It Possible to Differentiate the Two Disorders?The Journal of Clinical Endocrinology & Metabolism, 2000
- Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic ratsJournal of Clinical Investigation, 2000
- Functional characterization of calcium-sensing receptor mutations expressed in human embryonic kidney cells.Journal of Clinical Investigation, 1996